60 studies found for:    avid
Show Display Options
Rank Status Study
1 Withdrawn The Effects of Active VItamin D on Left Atrial Volume Index
Condition: Heart Failure
Intervention: Drug: Paricalcitol
2 Unknown  11C-Acetate PET/CT Non-FDG-Avid Tumors
Conditions: Soft Tissue Sarcomas;   Thyroid Cancer;   Lung Cancer;   Indolent Lymphoma;   Neuroendocrine Tumors;   GIST;   Uterine Malignancies;   Carcinoma, Hepatocellular;   Carcinoma, Lobular;   Teratoma
Intervention:
3 Completed Antiarrhythmics Versus Implantable Defibrillators (AVID)
Conditions: Arrhythmia;   Cardiovascular Diseases;   Death, Sudden, Cardiac;   Heart Diseases;   Tachycardia, Ventricular;   Ventricular Fibrillation
Interventions: Device: defibrillators, implantable;   Drug: amiodarone amiodarone;   Drug: sotalol
4 Recruiting Quantitative 18F-AV-133 PET Imaging in Subjects With Diabetes and Healthy Controls
Condition: Type 2 Diabetes
Interventions: Drug: 18F-AV-133;   Drug: 10% Arginine Hydrochloride-R-Gene 10
5 Recruiting Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Conditions: Alzheimer Disease;   Mild Cognitive Impairment;   Neurodegenerative Diseases
Intervention: Drug: Florbetapir F 18
6 Recruiting A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects With Parkinson's Disease (PD) From Other Movement Disorders
Conditions: Parkinson's Disease;   Primary Parkinsonism;   Lewy Body Parkinson's Disease
Intervention: Drug: 18F-AV-133
7 Recruiting Evaluation of Reader Training Processes
Condition: Alzheimer's Disease
Intervention: Drug: florbetapir F 18
8 Recruiting The Feasibility of Florbetapir Quantitation
Condition: Alzheimers Disease
Intervention: Drug: Florbetapir F18
9 Not yet recruiting Imaging Characteristics of a Follow-up 18F-AV-1451 Scan
Condition: Alzheimer's Disease
Interventions: Drug: 18F-AV-1451;   Drug: Florbetapir F 18
10 Not yet recruiting 18F-AV-1451 and Florbetapir F 18 PET Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy
Condition: Chronic Traumatic Encephalopathy
Interventions: Drug: florbetapir F 18;   Drug: 18F-AV-1451
11 Recruiting The Feasability of Florbetapir Quantitation in Europe
Condition: Alzheimer's Disease
Intervention: Drug: Florbetapir (18F)
12 Recruiting Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
Conditions: Disseminated Neuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4S Neuroblastoma
Interventions: Drug: doxorubicin hydrochloride;   Drug: irinotecan hydrochloride;   Other: pharmacological study;   Other: questionnaire administration;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: in vitro-treated peripheral blood stem cell transplantation;   Procedure: therapeutic conventional surgery;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: external beam radiation therapy;   Radiation: intensity-modulated radiation therapy;   Drug: cyclophosphamide;   Drug: topotecan hydrochloride;   Drug: cisplatin;   Drug: etoposide phosphate;   Drug: vincristine sulfate;   Radiation: iobenguane I 131;   Drug: busulfan;   Drug: melphalan;   Drug: isotretinoin
13 Recruiting PET/CT-Assessment of Liver Tumor Ablation
Conditions: Liver Tumor;   Liver Neoplasms
Interventions: Radiation: N-13 ammonia;   Device: PET/CT scanner
14 Not yet recruiting PET-MRI in Diagnosing Patients With Cancer, Cardiac Diseases, or Neurologic Diseases
Conditions: Cardiac Disease;   Dementia;   Inflammatory Disease;   Fever of Unknown Origin;   Vasculitis;   Osteomyelitis;   FDG Avid Cancers
Interventions: Procedure: positron emission tomography;   Procedure: computed tomography;   Procedure: magnetic resonance imaging
15 Recruiting Exercise in Asymptomatic Pre-Alzheimer's Disease Pilot Study
Condition: Alzheimer's Disease Prevention
Intervention: Behavioral: Aerobic vs. Non-Aerobic exercise
16 Active, not recruiting Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Condition: Alzheimer's Disease
Intervention: Drug: florbetapir (18F)
17 Completed
Has Results
Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)
Conditions: Alzheimer's Disease;   Mild Cognitive Impairment
Intervention: Drug: florbetapir F 18
18 Completed
Has Results
A Study of 18F-AV-45 in Healthy Volunteers
Condition: Alzheimer Disease
Intervention: Drug: florbetapir F 18
19 Completed
Has Results
Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain
Condition: Alzheimer's Disease
Intervention: Drug: florbetapir F 18
20 Completed
Has Results
A Study of Florbetapir (18F) in Japanese Healthy Volunteers
Condition: Alzheimer's Disease
Intervention: Drug: florbetapir (18F)

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years